Introduction to U.S. Drug Shortages CAPT Valerie Jensen, R.Ph. - - PDF document

▶
introduction to u s drug shortages
SMART_READER_LITE
LIVE PREVIEW

Introduction to U.S. Drug Shortages CAPT Valerie Jensen, R.Ph. - - PDF document

Feb 07, 2024 355 likes •467 views

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 Introduction to U.S. Drug Shortages CAPT Valerie Jensen, R.Ph. Associate Director Drug Shortage Program Center for Drug Evaluation & Research U.S. Food & Drug

slide-1
SLIDE 1

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 1

1

Introduction to U.S. Drug Shortages

CAPT Valerie Jensen, R.Ph. Associate Director Drug Shortage Program Center for Drug Evaluation & Research U.S. Food & Drug Administration

2

Overview

U.S. Drug Shortage Trends Reasons for Drug Shortages FDA’s Role View of the Future

slide-2
SLIDE 2

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 2

3

Drug Shortage Program History

  • Center for Drug Evaluation & Research

– Drug Shortage Program (DSP) began in 1999 – Today have 11 full time staff – Many others in involved

  • Mission: address potential and actual drug

shortages

– Facilitate prevention and resolution of shortages by collaborating with FDA experts, industry, and external stakeholders – Inform the public – Outreach to healthcare professional organizations, patient groups and other stakeholders

Who works on this?

Office of New Drugs Office of Chemistry Office of Generic Drugs Office of Compliance Field Inspectors MANY OTHERS!

4

Growing problem – and FDA response

  • FDA website updated daily
  • Staffing and management coordination
  • Public reports encouraged – industry reports of

problems even more so

  • Public workshop September 26, 2011
  • Collaboration on system fixes

– American Society of Healthcare Pharmacists (ASHP) – Industry (GPHA, PhRMA, BIO)

  • Prevent and mitigate individual shortages
slide-3
SLIDE 3

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 3

5

FDA Authorities are very limited

What we can require

  • Notification by sole

source manufacturers*

– For discontinuance of product – 6 months in advance – No penalty for not reporting

  • Notification of

manufacturing changes

What we can’t require

  • A company to make a

drug or make more

  • Notification of most

production delays, etc.

  • How much and to whom

drug is sold or distributed

FDA Drug Shortages Program is largely depends

  • n voluntary notification by manufacturers

and the public.

6

DISCONTINUANCE OF A LIFE SAVING PRODUCT

  • SEC. 506C. [ 21 U.S.C. 356c] DISCONTINUANCE OF A LIFE SAVING

PRODUCT. (a) IN GENERAL.—A manufacturer that is the sole manufacturer of a drug— (1) that is— (A) life-supporting; (B) life-sustaining; or (C) intended for use in the prevention of a debilitating disease or condition; (2) for which an application has been approved under section 505(b) or 505(j); and (3) that is not a product that was originally derived from human tissue and was replaced by a recombinant product, shall notify the Secretary of a discontinuance of the manufacture of the drug at least 6 months prior to the date of the discontinuance.

  • See also 21CFR 314.81(b)(3)(iii)
slide-4
SLIDE 4

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 4

7

U.S. Shortages

61 56 90 110 157 178 250 50 100 150 200 250 300 2005 2006 2007 2008 2009 2010 2011

Year

Number

All Sterile Injectables

8

Sterile Injectibles:

> 75% lapsed product quality & production

Product Quality 54% Delays, capacity and loss of manufacturing site 25% Discontinuations 11% Raw Materials 5% New demand 4% Other 2%

slide-5
SLIDE 5

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 5

9

2011 Shortage Data

  • Over 250 shortages reported in 2011
  • High percentage are sterile injectable

products

– Treatments for cancer, anesthesia, serious illness – Highly specialized manufacturing – High risk to patient if not meticulous

When there are quality or production problem for a sterile injectable drug, a shortage is almost always results

10

Reasons for Shortages: Sterile Injectibles

Report by Assistant Secretary for Planning & Evaluation 2011

  • State of the industry

– Seven (7) manufacturers make up most of market – Contract manufacturers – firms contract out manufacturing as well as acting as contract manufacturers

  • Lack of redundancy

– Multiple products made on existing manufacturing lines – 24/7 production with no ―cushion‖

  • Complex manufacturing process

– No simple fixes – Problems typically affect multiple products

  • Investment economics question

– e.g., leucovorin injection < $5.00/vial

slide-6
SLIDE 6

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 6

11

How does FDA fit?

  • Patient care is our #1 concern
  • We get involved when we are informed
  • Seek ways to prevent & mitigate shortages

– Secondary response to industry problem – Find root cause and get manufacturer on track

  • Some shortages can be prevented, but not all

– Unforseen breakdown in manufacturing system – Longstanding quality manufacturing problems

  • Some can be addressed quickly, others not

– Risks to the patient always considered

12

Quality and Manufacturing Examples

  • Sterility - bacterial and mold contamination
  • Particles of foreign matter

– glass, metal and fibers in vials

  • Crystallization of the active ingredient
  • Precipitate formation

– due to reaction with raw materials or container/stopper with the drug

  • New impurities or degradants
  • Equipment breakdown
  • Natural disasters
slide-7
SLIDE 7

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 7

13

FDA’s Approach to Prevention/Mitigation

  • Consider medical necessity
  • Risk/Benefit of the drug always considered
  • Do everything possible within our authority to

continue availability while minimizing risk to patients.

  • Work with firm to address

– We can advise, assist and expedite, but only the manufacturer can fix the problem

  • Be flexible and creative – and fast

14

Medical Necessity

  • A medically necessary drug product is a

product that is used to treat or prevent a serious disease or medical condition for which there is no other alternative drug, available in adequate supply, that is judged by medical staff to be an adequate substitute

CDER Manual of Policies and Procedures on Drug Shortage Management 6003.1

http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesPro cedures/UCM079936.pdf

slide-8
SLIDE 8

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 8

15

  • Regulatory discretion: allow manufacture of medically necessary product(s)

to continue

– Minor, low risk issues usually best suited for this tool – In some cases require additional safety controls

  • Filters packaged with product; extra testing at plant; 3rd party oversight of production;

special instructions for safe use

  • Request other firms to ramp up manufacturing.
  • Expedite any review of company proposals

– New manufacture site, increased expiry, new raw material source, changes in specifications, etc.

  • In rare cases, temporary importation from unapproved sources

– 2010 temporary importation of propofol – 2011 temporary importation of foscarnet, ethiodol, thiotepa, norepinephrine, Xeloda, levoleucovorin, leucovorin – 2012 temporary importation of Lipodox, methotrexate preservative free vials

FDA Tool Box

16

38 Shortages Prevented in 2010

  • All due to firms notifying FDA of problems early
  • 16 through regulatory discretion

– Risk of quality/manufacturing issue able to be mitigated and was

  • utweighed by benefit of the drug
  • 13 through expedited review

– New manufacturing sites, suppliers, etc.

  • 8 through encouraging other firms to ramp up
  • 1 through communication with DEA regarding firm’s

need for controlled substance quota increase

slide-9
SLIDE 9

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 9

17

2011 Data Higher – Executive Order

President’s Executive Order issued 10/31/11 encouraged more voluntary reporting by manufacturers

  • 6 fold increase in notifications of potential shortages

– normally received 10/month on average in 2010 and now receiving over 60 notifications per month)

  • Total of 195 shortages prevented in 2011
  • In 2012, 18 shortages prevented as of February 9, 2012

18

Shortages can’t always be prevented

  • Unanticipated problems, such as a

manufacturing line breakdown or natural disaster

  • Manufacturer(s) may not be able to make up

production shortfall

  • Risks are significant and would cause patient

harm (e.g. sterility problems)

  • FDA will work with company to encourage smart

distribution

– No easy answers on how to do this well

slide-10
SLIDE 10

As presented at the NCCS Cancer Policy Roundtable March 22-23, 2012 10

19

The Future

  • FDA Drug Shortage work will continue

– Multidisciplinary: clinicians, pharmacists, chemists, biotechnology, regulatory and manufacturing – We can only prevent shortages if problems are reported – Public communication of existing shortages

  • Congress discussing new legislation

– Would REQUIRE broader reporting by industry to FDA

  • Public expects and deserves high quality drugs
  • Must have industry commitment to culture of quality

manufacturing

– Many firms are building new plants today – Need better methods and redundancy – Promptly report and correct even small problems

20

Thank You

  • FDA drug shortage website is:

http://www.fda.gov/Drugs/DrugSafety/default.htm

  • To report shortages our e-mail account is

Drugshortages@fda.hhs.gov

  • FDA Webinar on Prescription Drug Shortages
  • Sept. 30, 2011,

http://www.fda.gov/AboutFDA/Transparency/Basics/ ucm272223.htm